Neurology Central

Could novel radiopharmaceuticals for PET imaging improve the way we diagnose Alzheimer’s?

A team of researchers from John Hopkins University (MD, USA) have evaluated the tau-specific binding abilities of three different radiopharmaceuticals and their potential to be used in PET imaging of tau proteins. The paper, which has been published in the Journal of Nuclear Medicine, identified radiotracers that have the potential to be utilized in a clinical setting for the diagnosis of Alzheimer’s disease (AD).

Tau tangles in the brain are one of the markers of AD and may be utilized as a therapeutic target for the treatment of this form of dementia.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.